Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Sun Pharma Halol facility gets 8 USFDA observations post GMP inspection

      Sun Pharma Halol facility gets 8 USFDA observations post GMP inspection

      Farhat Nasim14 Dec 2019 12:50 PM IST
      The U.S Food and Drug Administration (USFDA) conducted a Good Manufacturing Practices (GMP) inspection of the company's Halol facility (Gujarat,...
      NPPA raises MRP of 21 essential, life saving drugs by 50pc; Details

      NPPA raises MRP of 21 essential, life saving drugs by 50pc; Details

      Farhat Nasim14 Dec 2019 11:56 AM IST
      New Delhi: In a first, the apex drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), through a recent notification has...
      Biocon, Equillium expand license agreement for plaque psoriasis drug Itolizumab

      Biocon, Equillium expand license agreement for plaque psoriasis drug Itolizumab

      Farhat Nasim13 Dec 2019 3:37 PM IST
      Equillium had originally secured exclusive rights to develop and commercialize Biocon Ltd’s novel biologic, Itolizumab, for the U.S. and Canada...
      Hikal Gujarat facility gets EIR from USFDA

      Hikal Gujarat facility gets EIR from USFDA

      Farhat Nasim13 Dec 2019 3:07 PM IST
      The pharmaceutical manufacturing facility at Panoli in Gujarat was recently inspected by the US Food and Drug Administration (USFDA) in compliance...
      New Delhi: Elderly chemist murdered by Gym Trainer allegedly over purchase of viagra

      New Delhi: Elderly chemist murdered by Gym Trainer allegedly over purchase of viagra

      Farhat Nasim13 Dec 2019 1:32 PM IST
      New Delhi: In a shocking incident, a 50-year-old chemist was allegedly murdered by a gym trainer following an altercation over the purchase of viagra...
      Cipla associate Avenue Therapeutics files US application for IV tramadol

      Cipla associate Avenue Therapeutics files US application for IV tramadol

      Farhat Nasim12 Dec 2019 3:30 PM IST
      New Delhi: Cipla Ltd's associate company, Avenue Therapeutics, Inc. ("Avenue"), a company focused on the development of intravenous ("IV") tramadol...
      Sanofi, Regeneron to restructure antibody collaboration for Kevzara, Praluent

      Sanofi, Regeneron to restructure antibody collaboration for Kevzara, Praluent

      Farhat Nasim12 Dec 2019 9:20 AM IST
      Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected...
      CDSCO approves over 3000 global clinical trial sites, investigators; prepares comprehensive database

      CDSCO approves over 3000 global clinical trial sites, investigators; prepares comprehensive database

      Farhat Nasim11 Dec 2019 2:41 PM IST
      CDSCO is preparing a comprehensive database of sites and investigators involved in the conduct of the clinical trial in different therapeutic...
      Merck to acquire cancer drug developer ArQule for USD 2.7 billion

      Merck to acquire cancer drug developer ArQule for USD 2.7 billion

      Farhat Nasim11 Dec 2019 9:30 AM IST
      New Delhi: Merck, known as MSD outside the United States and Canada, and ArQule, Inc. recently announced that the companies have entered into a...
      Transasia Bio-Medicals names Medtronic biz director Ravi Kaushik as new CEO

      Transasia Bio-Medicals names Medtronic biz director Ravi Kaushik as new CEO

      Farhat Nasim11 Dec 2019 9:17 AM IST
      Prior to this appointment at Transasia Bio-Medicals, Ravi Kaushik was Group Marketing Director - Asia Pacific & Country Business Director -...
      Roche secures CE Mark for Accu-Chek SugarView app for diabetes management

      Roche secures CE Mark for Accu-Chek SugarView app for diabetes management

      Farhat Nasim10 Dec 2019 1:07 PM IST
      Now officially classified as in-vitro diagnostics (IVD) software, the app will be made widely accessible by Roche first for certain smartphone models...
      Dr Reddys unveils generic Deferasirox Tablets in US

      Dr Reddys unveils generic Deferasirox Tablets in US

      Farhat Nasim10 Dec 2019 12:53 PM IST
      The two different products launched by Dr Reddy's Labs in the US market are generic versions of Exjade (deferasirox) and Jadenu (deferasirox)...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok